Apimeds Pharmaceuticals US (APUS) Convertible Debt (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Convertible Debt of $151237.0 for Q3 2025, little changed quarter-over-quarter from $151237.0 in Q2 2025.

Apimeds Pharmaceuticals US (APUS) Convertible Debt (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Convertible Debt for 2 years, with the latest figure at $151237.0 in Q3 2025.

For the quarter ending Q3 2025, Convertible Debt changed N/A year-over-year to $151237.0; the trailing twelve-month figure through Sep 2025 stood at $151237.0 (changed N/A YoY), and the FY2024 full-year result was $346844.0, changed N/A from the prior year.
Convertible Debt for Q3 2025 stood at $151237.0, roughly flat from $151237.0 in the prior quarter.
The five-year high for Convertible Debt was $346844.0 in Q4 2024, with the low at $151237.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Apimeds Pharmaceuticals US	13.93 Mn	10.29 Mn	-

Download Data